WallStSmart
IMCR

Immunocore Holdings Ltd

NASDAQ: IMCR · HEALTHCARE · BIOTECHNOLOGY

$27.92
-3.02% today

Updated 2026-04-29

Market cap
$1.42B
P/E ratio
P/S ratio
3.55x
EPS (TTM)
$-0.71
Dividend yield
52W range
$27 – $41
Volume
0.4M

Immunocore Holdings Ltd (IMCR) Stock Valuation Analysis

Fair value estimate, historical valuation range, and quality signals for IMCR.

WallStSmart Verdict
Overvalued

Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.

Smart Value Score: 43 / 100
P/E (TTM)
Not meaningful for this profile
PEG
Margin of Safety
+2.46%
Fair value $33.76 vs $27.92
EV / EBITDA
0.0x

IMCR historical valuation range

Where current P/E sits in IMCR's own 5Y range.

Insufficient historical data for 5Y percentile analysis

IMCR intrinsic value (DCF)

DCF-based fair value estimate vs current market price.

Current price
$27.92
Market value
Intrinsic value
$33.76
DCF estimate
Margin of safety
+2.46%
+20.9% upside to fair value

Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.

IMCR valuation signals

Quick-read green flags, caution flags, and risks based on current metrics.

!
Near fair value
+2.46% margin of safety. Price is close to DCF estimate.
Weak financial quality
Piotroski F-Score of 0/9 suggests deteriorating fundamentals. Valuation requires closer scrutiny.

P/E Ratio — History

No historical P/E data available

P/S Ratio — History

Current: 3.55x

Is IMCR overvalued in 2026?

Immunocore Holdings Ltd (IMCR) currently trades at $27.92 per share with a market capitalization of $1,419,227,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 43/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.

IMCR currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 3.5x, the market is valuing the company primarily on its revenue rather than its earnings.

Our discounted cash flow model estimates IMCR's intrinsic value at $33.76 per share, against the current market price of $27.92. This implies a margin of safety of +2.46%. The stock is priced close to its estimated fair value, offering limited upside without further operational improvement.

Financial quality is a concern. The Piotroski F-Score of 0/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.

Bottom line: IMCR appears richly valued on our framework, with a Smart Value Score of 43/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.

Frequently asked questions

Is IMCR overvalued in 2026?

Based on a Smart Value Score of 43/100, IMCR appears overvalued. Current price exceeds what fundamentals currently justify.

What is IMCR's fair value?

Our DCF model estimates IMCR's intrinsic value at $33.76 per share, versus the current price of $27.92. This produces a margin of safety of +2.46%.

What P/E ratio does IMCR trade at?

IMCR does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.

Is IMCR a buy based on valuation?

WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 43/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.

How does IMCR's valuation compare to its history?

Insufficient historical valuation data exists yet for a confident percentile read on IMCR.

What is IMCR's Smart Value Score?

IMCR's Smart Value Score is 43/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.